<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LOPERAMIDE<img border="0" src="../images/pr.gif"/></span><br/>(loe-per'a-mide)<br/><span class="topboxtradename">Imodium, </span><span class="topboxtradename">Imodium AD, </span><span class="topboxtradename">Kaopectate III, </span><span class="topboxtradename">Maalox Anti-diarrheal, </span><span class="topboxtradename">Pepto Diarrhea Control<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">antidiarrheal</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg tablets, capsules; 1 mg/mL, 1 mg/5 mL liquid</p>
<h1><a name="action">Actions</a></h1>
<p>Effective antidiarrheal; synthetic piperidine derivative chemically related to diphenoxylate and to meperidine. Reportedly
         has longer duration of action.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits GI peristaltic activity by direct action on circular and longitudinal intestinal muscles. Prolongs transit time of
         intestinal contents, increases consistency of stools, and reduces fluid and electrolyte loss.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Acute nonspecific diarrhea, chronic diarrhea associated with inflammatory bowel disease, and to reduce fecal volume from ileostomies.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Conditions in which constipation should be avoided, severe colitis, acute diarrhea caused by broad-spectrum antibiotics (pseudomembranous
         colitis) or associated with microorganisms that penetrate intestinal mucosa (e.g., toxigenic <i>Escherichia coli, Salmonella,</i> or <i>Shigella</i>). Safe use during pregnancy (category B), lactation, or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Dehydration; diarrhea caused by invasive bacteria; impaired liver function; prostatic hypertrophy; history of narcotic dependence.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Diarrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 4 mg followed by 2 mg after each unformed stool (max: 16 mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>26 y</i>, 1 mg t.i.d.; <i>68 y</i>, 2 mg b.i.d.; <i>812 y</i>, 2 mg t.i.d.<br/><br/><span class="indicationtitle">Chronic Diarrhea</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 4 mg followed by 2 mg after each unformed stool until diarrhea is controlled (max: 16 mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.1 mg/kg after each unformed stool (usually 1 mg)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not give prn doses to a child with acute diarrhea.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity (skin rash); fever. <span class="typehead">CNS:</span> Drowsiness, fatigue, dizziness, CNS depression (overdosage). <span class="typehead">GI:</span> Abdominal discomfort or pain, abdominal distention, bloating, constipation, nausea, vomiting, anorexia, dry mouth; <span class="speceff-life">toxic megacolon</span> (patients with ulcerative colitis). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Poorly absorbed from GI tract. <span class="typehead">Onset:</span> 3060 min. <span class="typehead">Peak:</span> 2.5 h solution; 45 h capsules. <span class="typehead">Duration:</span> 45 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Primarily excreted in feces, Half-Life: 11 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor therapeutic effectiveness. Chronic diarrhea usually responds within 10 d. If improvement does not occur within this
            time, it is unlikely that symptoms will be controlled by further administration.
         </li>
<li>Discontinue if there is no improvement after 48 h of therapy for acute diarrhea.</li>
<li>Monitor fluid and electrolyte balance.</li>
<li>Notify physician promptly if the patient with ulcerative colitis develops abdominal distention or other GI symptoms (possible
            signs of potentially fatal toxic megacolon).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician if diarrhea does not stop in a few days or if abdominal pain, distension, or fever develops.</li>
<li>Record number and consistency of stools.</li>
<li>Do not drive or engage in other potentially hazardous activities until response to drug is known.</li>
<li>Do not take alcohol and other CNS depressants concomitantly unless otherwise advised by physician; may enhance drowsiness.</li>
<li>Learn measures to relieve dry mouth; rinse mouth frequently with water, suck hard candy.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>